The association between the p53/ topoisomerase I and p53/ topoisomerase IIα immunophenotypes and the progression of ovarian carcinomas

Advances in Clinical and Experimental Medicine

Volumn 21, Issue 1, 2012, Pages 35-42

  Bar, Julia K ^a   Grelewski, Piotr ^a   Noga, Leszek ^a   Rabczyński, Jerzy ^a   Gryboś, Marian ^a   Jeleń, Michał ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Immunohistochemistry; Ovarian neoplasms; p53 protein; Progression; Topoisomerases

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; ISOMERASE; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; OVARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 84859173071     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley TB: Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2008, 111, 487-495.
2. Materna V, Pleger J, Hoffmann U, and Lage H: RMA expression of MDR1/P- glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004, 94, 152-160.
3. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehi E, Palmer Ch, Leung S, Bowen N.J, Ionescu DN, Rajput A, Prentice, LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D: Ovarian carcinoma subtypes are different diseases; implications for biomarkers studies. POLS 2008, 12, 1749-1759.
4. Cai QK, Wu H, Klein-Szanto AJ, Xu XX: Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. Gynecol Oncol 2009, 1, 18-25.
5. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG: Prognostic factors associated with response in platinum retreatment of platinum-resistance ovarian cancer. Int J Gynecol Cancer 2008, 16, 1194-1199.
6. Lee YK, Park NH: Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol 2009, 112, 475-480.
7. Orlando L, Curto BD, Gandini S, Ghisini R, Pietri E Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M: Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008, 17, 506-517.
8. Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli, J, Dahi E: Altered expression pattern of topoisomerase IIα in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 2006, 1, 38-45.
9. Lee SJ, Kim HS, Kim HS, Chun VK, Hong SR, Lee JH: Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas. Human Pathol 2007, 238, 1226-1231.
10. Hande KR: Topoisomerase II inhibitors. Update Cancer Therapeutics 2006, 1, 3-15.
11. Valkov NI, Sullivan DM: Tumor p53 status and response to topoisomerase II inhibitors. Drug Resistance Updates 2003, 6, 27-39.
12. Koshiyama M, Fuji H, Kinezaki M, Yoshida M: Correlation between Topo Ha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Res 2001, 21, 905-10.
13. Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Berda E, Savarese E, Scambia G: Prognostic role of topoisomerase Ha in advanced ovarian cancer patients. Brt J Cancer 2008, 98, 1910-1915.
14. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti A: Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol/Hematol 2006, 60, 19-37.
15. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick B: Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006, 100, 152-159.
16. Mao Y, Okad S, Chang LS, Muller MT: p53 dependence of topoisomerase I recruitment in vivo. Cancer Res 2000, 60, 4538-4543.
17. Tomicic MT, Christmann M, Kain B: Topotecan-tiggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res 2005, 65, 8920-8926.
18. Wang Q, Zamnetti GP, Suttle DP: Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor sup- pressor. Mol Cellular Biol 1997, 17, 389-397.
19. Sandri MI, Isaacs J, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F: p53 regulates the minimal promoter of the human topoisomerase IIα gene. Nucleic Acids Res 1996, 24, 4464-4470.
20. Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M: Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in ovarian carcinoma. Gynecol Oncol 2004, 92, 887-895.
21. Brustmann H: Vascular endothelial growth factor expression in serous carcinoma: relationship with topoisomerase IIαand prognosis. Gynaecol Oncol 2004, 95, 16-27.
22. Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, Rack B, Sommer H, Friese K: Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIα, epidermal growth factor receptor, and nm23 expression in ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer 2007, 17, 1047-1055.
23. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shmogai R, Kawaguchi W, Sato S, Terakawa N: Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007, 12, 76-82.
24. Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefever B, Pluot M: Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase IIα, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 2000, 35, 745-751.
25. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M: Topoisomerase IA, HER2/neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histolopathol 2006, 7, 713-720.
26. Hagdall EVS, Christensen L, Hogdall CK, Frederiksen K, Gaythe S, Blaakaer J, Jacobs IJ, Kjaer K: Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. AMPIS 2008, 116, 400-409.